Bill & Melinda Gates Foundation Trust holds the investments for Bill Gates' second career - philanthrophy. It is run by Michael Lassen, who also manages Cascade Investments, Bill Gates' personal portfolio. Bill & Melinda Gates Foundation Trust owns similar stocks as Cascade, except more stocks and more shares. This is the Q2 portfolio update of Bill & Melinda Gates Foundation Trust.
Bill & Melinda Gates Foundation buys CSX Corp., M&T Bank Corp., XTO Energy Inc., America Movil S.a.b. De C.v., Range Resources Corp., Cabot Oil & Gas Corp., Devon Energy Corp., sells Vertex Pharmaceuticals Inc., Aryx Therapeutics Inc., Regeneron Pharmaceuticals Inc., Ardea Biosciences, Inc., Pfizer Inc, Mylan Inc. Mandatory Convertible Preferr, Map Pharmaceuticals, Inc., Eli Lilly And Company, Johnson & Johnson, Intermune Inc., Biomarin Pharmaceutical Inc., Amag Pharmaceuticals Inc., Orexigen Therapeutics Inc., Allos Therapeutics Inc., Auxilium Pharmaceuticals Inc., Pharmasset Inc., Wyeth, Select Sector Spdrhealth Care, Xenoport Inc., Teva Pharmaceutical Industries Ltd., Scheringplough Corp., Merck & Co. Inc., Incyte Corp., Enteromedics Inc., China Medical Technologies Inc. Ads, Baxter International Inc., Abbott Laboratories during the 3-months ended 06/30/2009, according to the most recent filings of his investment company, Bill & Melinda Gates Foundation Trust. Bill Gates owns 38 stocks with a total value of $7.5 billion. These are the details of the buys and sells. New Purchases: AMX, COG, CSX, DVN, MTB, RRC, XTO,
Added Positions: MCD, TV,
Sold Out: ABT, ALTH, AMAG, ARYX, AUXL, BAX, BMRN, CMED, ETRM, INCY, ITMN, JNJ, LLY, MAPP, MRK, MYLNP, OREX, PFE, RDEA, REGN, SGP, TEVA, VRTX, VRUS, WYE, XLV, XNPT,
For the details of Bill Gates's stock buys and sells, go to the Link Here
This is the sector weightings of Bill Gates's portfolio:
These are the top 5 holdings of Bill Gates
Added: McDonald's Corp. (MCD, Financial)
Bill Gates added to his holdings in McDonald's Corp. by 7.85%. His purchase prices were between $51.97 and $59.87, with an estimated average price of $56.1. The impact to his portfolio due to this purchase was 0.38%. His holdings were 6,867,500 shares as of 06/30/2009.
McDonald's Corporation develops operates franchises and services a worldwide system of restaurants that prepare assemble package and sell a limited menu of value-priced foods. The company operates primarily in the quick-service hamburger restaurant business. All restaurants are operated by the company or under the terms of franchise arrangements by franchisees who are independent third parties or by affiliates operating under joint-venture agreements between the company and local business people. McDonald's Corp. has a market cap of $63.06 billion; its shares were traded at around $57.16 with a P/E ratio of 15.2 and P/S ratio of 2.6. The dividend yield of McDonald's Corp. stocks is 3.6%. McDonald's Corp. had an annual average earning growth of 7.2% over the past 10 years.
Added: Grupo Televisa S.a. Global Depositary (TV, Financial)
Bill Gates added to his holdings in Grupo Televisa S.a. Global Depositary by 20.86%. His purchase prices were between $15.19 and $17.78, with an estimated average price of $16.6. The impact to his portfolio due to this purchase was 0.34%. His holdings were 8,690,800 shares as of 06/30/2009.
Grupo Televisa S.A is the largest media company in the Spanish-speaking world and a major player in the international entertainment business. They have interests in Television production broadcasting international distribution of television programming direct-to-home satellite services publishing music recording radio production and broadcasting cable television professional sports and show business promotions paging services feature film production and distribution and dubbing. with a P/E ratio of 447.6. The dividend yield of Grupo Televisa S.a. Global Depositary stocks is 3.7%. Grupo Televisa S.a. Global Depositary had an annual average earning growth of 12.3% over the past 10 years. GuruFocus rated Grupo Televisa S.a. Global Depositary the business predictability rank of 3-star.
New Purchase: CSX Corp. (CSX, Financial)
Bill Gates initiated holdings in CSX Corp.. His purchase prices were between $27.47 and $36.52, with an estimated average price of $31.7. The impact to his portfolio due to this purchase was 0.69%. His holdings were 1,500,000 shares as of 06/30/2009.
CSX Corporation's unique combination of rail container-shipping intermodal and logistics services provides global reach that's second to none. The company's goal advanced at each of its business units is to provide efficient competitive transportation and related services for customers. CSX Corp. has a market cap of $17.01 billion; its shares were traded at around $43.46 with a P/E ratio of 13.7 and P/S ratio of 1.5. The dividend yield of CSX Corp. stocks is 2.1%. CSX Corp. had an annual average earning growth of 12.8% over the past 10 years.
New Purchase: M&T Bank Corp. (MTB, Financial)
Bill Gates initiated holdings in M&T Bank Corp.. His purchase prices were between $45.5 and $59.11, with an estimated average price of $50.3. The impact to his portfolio due to this purchase was 0.68%. His holdings were 999,998 shares as of 06/30/2009.
M&T Bank Corp is a bank holding company. They have two primary bank subsidiaries: Manufacturers and Traders Trust Company and M&T Bank National Association. The banks collectively offer a wide range ofcommercial banking trust and investment services to their customers. From time to time M&T Bank considers acquiring banks thrift institutionsbranch offices or other businesses within markets currently served or in other nearby markets. M&T Bank Corp. has a market cap of $6.8 billion; its shares were traded at around $61.24 with a P/E ratio of 21.5 and P/S ratio of 1.6. The dividend yield of M&T Bank Corp. stocks is 4.6%. M&T Bank Corp. had an annual average earning growth of 10.2% over the past 10 years. GuruFocus rated M&T Bank Corp. the business predictability rank of 4-star.
New Purchase: XTO Energy Inc. (XTO, Financial)
Bill Gates initiated holdings in XTO Energy Inc.. His purchase prices were between $33.1 and $44.13, with an estimated average price of $38.8. The impact to his portfolio due to this purchase was 0.62%. His holdings were 1,210,000 shares as of 06/30/2009.
XTO Energy Inc. is engaged in the acquisition development exploitation and exploration of producing oil and gas properties and in the production processing marketing and transportation of oil and natural gas. The company has grown primarily through acquisitions of proved oil and gas reserves followed by development and exploitation activities and strategic acquisitions of additional interests in or near such acquired properties. XTO Energy Inc. has a market cap of $22.63 billion; its shares were traded at around $39.04 with a P/E ratio of 11.3 and P/S ratio of 3. The dividend yield of XTO Energy Inc. stocks is 1.2%. XTO Energy Inc. had an annual average earning growth of 36.6% over the past 10 years. GuruFocus rated XTO Energy Inc. the business predictability rank of 5-star.
New Purchase: America Movil S.a.b. De C.v. (AMX, Financial)
Bill Gates initiated holdings in America Movil S.a.b. De C.v.. His purchase prices were between $30.98 and $38.32, with an estimated average price of $35.5. The impact to his portfolio due to this purchase was 0.52%. His holdings were 999,984 shares as of 06/30/2009.
American Movil is the leading provider of wireless communications services in Mexico. Through their subsidiary Radiom?vil Dipsa which operates under the trademark Telcel they provide cellular telecommunications service in all nine regions in Mexico with a network covering approximately 31.4% of the geographical area of Mexico including all major cities and approximately 89.6% of Mexico 's population. America Movil S.a.b. De C.v. has a market cap of $84.17 billion; its shares were traded at around $46.76 with a P/E ratio of 14.7 and P/S ratio of 3.3. The dividend yield of America Movil S.a.b. De C.v. stocks is 1%. America Movil S.a.b. De C.v. had an annual average earning growth of 45.5% over the past 5 years.
New Purchase: Cabot Oil & Gas Corp. (COG, Financial)
Bill Gates initiated holdings in Cabot Oil & Gas Corp.. His purchase prices were between $28.34 and $35.56, with an estimated average price of $31.8. The impact to his portfolio due to this purchase was 0.32%. His holdings were 775,550 shares as of 06/30/2009.
Cabot Oil & Gas Corp. is an independent oil and gas company engaged in the exploration development acquisition and exploitation of oil and gas properties located in four areas of the United States: the onshore Texas and Louisiana Gulf Coast; the Rocky Mountains; Appalachia; and the Mid-Continent or Anadarko Basin. Cabot Oil & Gas Corp. has a market cap of $3.77 billion; its shares were traded at around $36.4 with a P/E ratio of 21.1 and P/S ratio of 4. The dividend yield of Cabot Oil & Gas Corp. stocks is 0.3%. Cabot Oil & Gas Corp. had an annual average earning growth of 16.2% over the past 10 years. GuruFocus rated Cabot Oil & Gas Corp. the business predictability rank of 4-star.
New Purchase: Range Resources Corp. (RRC, Financial)
Bill Gates initiated holdings in Range Resources Corp.. His purchase prices were between $39.89 and $46.81, with an estimated average price of $43.4. The impact to his portfolio due to this purchase was 0.32%. His holdings were 575,000 shares as of 06/30/2009.
Range Resources Corp. acquires develops and finances oil and gas properties in the U.S. They seek to build value primarily through lower-risk development drilling and acquisitions while to a lesser degree pursuing higher risk exploitation and exploration projects on their extensive inventory of undeveloped acreage. Through its wholly owned subsidiary Independent Producer Finance the company also provides financing to small oil and gas producers by purchasing term overriding royalty interests in their properties. Range Resources Corp. has a market cap of $7.8 billion; its shares were traded at around $49.83 with a P/E ratio of 44.9 and P/S ratio of 6. The dividend yield of Range Resources Corp. stocks is 0.3%. Range Resources Corp. had an annual average earning growth of 4.1% over the past 10 years.
New Purchase: Devon Energy Corp. (DVN, Financial)
Bill Gates initiated holdings in Devon Energy Corp.. His purchase prices were between $48.79 and $65.53, with an estimated average price of $58.1. The impact to his portfolio due to this purchase was 0.3%. His holdings were 407,500 shares as of 06/30/2009.
Devon Energy Corporation is an independent energy company engaged primarily in oil and gas exploration development and production and in the acquisition of producing properties. Devon currently owns oil and gas properties concentrated in four operating divisions: the Northern Division; the Southern Division; Canada; and the International Division. Devon Energy Corp. has a market cap of $27.58 billion; its shares were traded at around $62.13 with a P/E ratio of 12.2 and P/S ratio of 1.9. The dividend yield of Devon Energy Corp. stocks is 1%. Devon Energy Corp. had an annual average earning growth of 18.1% over the past 10 years. GuruFocus rated Devon Energy Corp. the business predictability rank of 4.5-star.
Sold Out: Johnson & Johnson (JNJ, Financial)
Bill Gates sold out his holdings in Johnson & Johnson. His sale prices were between $50.07 and $56.14, with an estimated average price of $53.7.
Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. The company's worldwide business is divided into three segments: Consumer; Pharmaceutical; and Professional. Johnson & Johnson has a market cap of $166.68 billion; its shares were traded at around $60.49 with a P/E ratio of 13.5 and P/S ratio of 2.7. The dividend yield of Johnson & Johnson stocks is 3.2%. Johnson & Johnson had an annual average earning growth of 12.5% over the past 10 years. GuruFocus rated Johnson & Johnson the business predictability rank of 4.5-star.
Sold Out: Aryx Therapeutics Inc. (ARYX, Financial)
Bill Gates sold out his holdings in Aryx Therapeutics Inc.. His sale prices were between $3.47 and $5.98, with an estimated average price of $4.4.
ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has three products in Phase 2 clinical trials: ATI-7505 for the treatment of various gastrointestinal disorders ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots and ATI-2042 for the treatment of atrial fibrillation. Aryx Therapeutics Inc. has a market cap of $97.7 million; its shares were traded at around $3.57 with and P/S ratio of 5.
Sold Out: Regeneron Pharmaceuticals Inc. (REGN, Financial)
Bill Gates sold out his holdings in Regeneron Pharmaceuticals Inc.. His sale prices were between $12.94 and $18.21, with an estimated average price of $15.2.
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers develops and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM FunctionomicsTM and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity rheumatoid arthritis cancer allergies asthma amyotrophic lateral sclerosis constipating conditions ischemia and other diseases and disorders. (PRESS RELEASE) Regeneron Pharmaceuticals Inc. has a market cap of $1.82 billion; its shares were traded at around $22.77 with and P/S ratio of 7.6.
Sold Out: Ardea Biosciences, Inc. (RDEA)
Bill Gates sold out his holdings in Ardea Biosciences, Inc.. His sale prices were between $9.33 and $15.73, with an estimated average price of $13.6.
IntraBiotics Pharmaceuticals Inc. develops and intends to commercialize new antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. The company obtained statistically significant data from human clinical trials that test for preliminary safety and efficacy that indicate each of the products are well tolerated and support further efficacy trials. The new antibiotics may solve medical problems for patients who have few or no satisfactory alternatives. Ardea Biosciences, Inc. has a market cap of $331.4 million; its shares were traded at around $18.56 with and P/S ratio of 1090.1.
Sold Out: Pfizer Inc (PFE)
Bill Gates sold out his holdings in Pfizer Inc. His sale prices were between $12.89 and $15.04, with an estimated average price of $14.3.
Pfizer Inc is a research-based global pharmaceutical company that discovers and develops innovative value-added products that improve the quality of life of people around the world and help them enjoy longer healthier and more productive lives. Pfizer has three business segments: health care animal health and consumer health care. Its products are available in numerous countries. (Company Press Release) Pfizer Inc has a market cap of $113.77 billion; its shares were traded at around $16.86 with a P/E ratio of 7.3 and P/S ratio of 2.3. The dividend yield of Pfizer Inc stocks is 3.8%. Pfizer Inc had an annual average earning growth of 11% over the past 10 years. GuruFocus rated Pfizer Inc the business predictability rank of 2.5-star.
Sold Out: Intermune Inc. (ITMN)
Bill Gates sold out his holdings in Intermune Inc.. His sale prices were between $11.32 and $15.18, with an estimated average price of $13.
InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas several of which are in mid-or advanced-stage human testing known as clinical trials. Intermune Inc. has a market cap of $718.7 million; its shares were traded at around $15.6 with and P/S ratio of 14.9.
Sold Out: Map Pharmaceuticals, Inc. (MAPP)
Bill Gates sold out his holdings in Map Pharmaceuticals, Inc.. His sale prices were between $2.65 and $12.09, with an estimated average price of $6.4.
Located in Mountain View California MAP Pharmaceuticals Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Map Pharmaceuticals, Inc. has a market cap of $192.2 million; its shares were traded at around $9.33 .
Sold Out: Eli Lilly And Company (LLY)
Bill Gates sold out his holdings in Eli Lilly And Company. His sale prices were between $31.73 and $34.94, with an estimated average price of $33.5.
Eli Lilly and Company discovers develops manufactures and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Eli Lilly And Company has a market cap of $39.19 billion; its shares were traded at around $34.11 with a P/E ratio of 7.7 and P/S ratio of 1.9. The dividend yield of Eli Lilly And Company stocks is 5.7%. Eli Lilly And Company had an annual average earning growth of 4.4% over the past 10 years. GuruFocus rated Eli Lilly And Company the business predictability rank of 4.5-star.
Sold Out: Biomarin Pharmaceutical Inc. (BMRN)
Bill Gates sold out his holdings in Biomarin Pharmaceutical Inc.. His sale prices were between $12.42 and $15.94, with an estimated average price of $14.
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating life-threatening chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product BM101 for the treatment of mucopolysaccharidosis-I or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans. Biomarin Pharmaceutical Inc. has a market cap of $1.61 billion; its shares were traded at around $16.07 with a P/E ratio of 133.8 and P/S ratio of 5.5.
Sold Out: Amag Pharmaceuticals Inc. (AMAG)
Bill Gates sold out his holdings in Amag Pharmaceuticals Inc.. His sale prices were between $40.32 and $54.64, with an estimated average price of $50.2.
AMAG Pharmaceuticals Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol the company's key product candidate is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex? the company's other product under development is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005 the company received an approvable letter from the FDA with respect to Combidex subject to certain conditions. Amag Pharmaceuticals Inc. has a market cap of $709.4 million; its shares were traded at around $41.67 with and P/S ratio of 366.
Sold Out: Orexigen Therapeutics Inc. (OREX)
Bill Gates sold out his holdings in Orexigen Therapeutics Inc.. His sale prices were between $2.06 and $5.21, with an estimated average price of $3.4.
OREXIGEN THERAPEUTICS INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders including obesity. The Company's lead combination product candidates targeted for obesity are Contrave which is in Phase III clinical trials and Empatic which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Orexigen Therapeutics Inc. has a market cap of $283.5 million; its shares were traded at around $8.17 with and P/S ratio of 3221.6.
Sold Out: Pharmasset Inc. (VRUS)
Bill Gates sold out his holdings in Pharmasset Inc.. His sale prices were between $8.55 and $11.46, with an estimated average price of $10.
PHARMASSET INC is a clinical-stage pharmaceutical company committed to discovering developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus hepatitis C virusand human immunodeficiency virus. Pharmasset Inc. has a market cap of $507.4 million; its shares were traded at around $18.05 with and P/S ratio of 273.3.
Sold Out: Wyeth (WYE)
Bill Gates sold out his holdings in Wyeth. His sale prices were between $41.55 and $44.74, with an estimated average price of $43.5.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery development manufacturing and marketing of pharmaceuticals vaccines biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals Wyeth Consumer Healthcare and Fort Dodge Animal Health. Wyeth has a market cap of $64.17 billion; its shares were traded at around $48.11 with a P/E ratio of 13.6 and P/S ratio of 2.8. The dividend yield of Wyeth stocks is 2.5%. Wyeth had an annual average earning growth of 5.8% over the past 10 years.
Sold Out: Xenoport Inc. (XNPT)
Bill Gates sold out his holdings in Xenoport Inc.. His sale prices were between $14.27 and $21.41, with an estimated average price of $18.5.
XenoPort Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs. Xenoport Inc. has a market cap of $492.4 million; its shares were traded at around $18.03 with and P/S ratio of 11.7.
Sold Out: Teva Pharmaceutical Industries Ltd. (TEVA)
Bill Gates sold out his holdings in Teva Pharmaceutical Industries Ltd.. His sale prices were between $43.89 and $48.6, with an estimated average price of $45.9.
TEVA Pharmaceuticals USA the business is to develop manufacture and market generic pharmaceuticals. Teva USA sells its products to chains wholesalers distributors hospitals managed care entities and government agencies. The company markets a variety of dosage forms including both extended and immediate release tablets and capsules creams ointments solutions and suspensions. Key therapeutic areas are the analgesic anti-infective cardiovascular CNS dermatological and anti-inflammatory categories. Teva Pharmaceutical Industries Ltd. has a market cap of $44.91 billion; its shares were traded at around $51.38 with a P/E ratio of 17 and P/S ratio of 4. The dividend yield of Teva Pharmaceutical Industries Ltd. stocks is 0.9%. Teva Pharmaceutical Industries Ltd. had an annual average earning growth of 42.6% over the past 10 years. GuruFocus rated Teva Pharmaceutical Industries Ltd. the business predictability rank of 2.5-star.
Sold Out: Scheringplough Corp. (SGP)
Bill Gates sold out his holdings in Scheringplough Corp.. His sale prices were between $22.05 and $24.5, with an estimated average price of $23.4.
Schering-Plough Corporation and its subsidiaries are engaged in the discovery development manufacturing and marketing of pharmaceutical products worldwide. The company operates primarily in the prescription pharmaceutical marketplace. However where appropriate the company has sought regulatory approval to switch prescription products to over-the-counter status as a means of extending a product's life cycle. Scheringplough Corp. has a market cap of $46.28 billion; its shares were traded at around $28.33 with a P/E ratio of 15.7 and P/S ratio of 2.5. The dividend yield of Scheringplough Corp. stocks is 0.9%.
Sold Out: Merck & Co. Inc. (MRK)
Bill Gates sold out his holdings in Merck & Co. Inc.. His sale prices were between $23.13 and $27.2, with an estimated average price of $25.5.
Merck & Co. Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891 Merck discovers develops manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Merck & Co. Inc. has a market cap of $69.32 billion; its shares were traded at around $32.87 with a P/E ratio of 10.1 and P/S ratio of 2.9. The dividend yield of Merck & Co. Inc. stocks is 4.6%.
Sold Out: Incyte Corp. (INCY)
Bill Gates sold out his holdings in Incyte Corp.. His sale prices were between $2.17 and $3.84, with an estimated average price of $2.9.
Incyte Corp is a drug discovery company that is using its expertise in genomics medicinal chemistry and molecular cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer. Incyte Corp. has a market cap of $624.9 million; its shares were traded at around $6.42 with and P/S ratio of 159.4. Incyte Corp. had an annual average earning growth of 6.9% over the past 5 years.
Sold Out: Enteromedics Inc. (ETRM)
Bill Gates sold out his holdings in Enteromedics Inc.. His sale prices were between $1.28 and $3.9, with an estimated average price of $2.5.
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity and following an in-depth analysis of how the vagus nerve affects food intake and processing EnteroMedics has selected obesity management as its primary focus. Enteromedics Inc. has a market cap of $98.5 million; its shares were traded at around $3.28 .
Sold Out: China Medical Technologies Inc. Ads (CMED)
Bill Gates sold out his holdings in China Medical Technologies Inc. Ads. His sale prices were between $18.11 and $24.93, with an estimated average price of $21.3.
China Medical Technologies Inc. is a China-based medical device company that develops manufactures and markets products using HIFU for the treatment of solid cancers and benign tumors in China. They design and development HIFU tumor therapy devices in China. Their HIFU therapy system is SFDA-approved and has been used to treat over 20000 patient cases. In addition they offer an integrated luminescence immunoassay IVD system using ECLIA technology to detect and monitor various diseases and disorders through laboratory evaluation and analysis of blood or urine. China Medical Technologies Inc. Ads has a market cap of $429.2 million; its shares were traded at around $15.69 with a P/E ratio of 6.7 and P/S ratio of 3.5.
Sold Out: Baxter International Inc. (BAX)
Bill Gates sold out his holdings in Baxter International Inc.. His sale prices were between $47.3 and $52.25, with an estimated average price of $49.8.
Baxter engages in the worldwide development manufacture and distribution of a diversified line of products systems and services used primarily in the health-care field. The company's products are used by hospitals clinical and medical research laboratories blood and dialysis centers rehabilitation centers nursing homes doctors' offices and by patients at home under physician supervision. Baxter International Inc. has a market cap of $34.38 billion; its shares were traded at around $56.82 with a P/E ratio of 15.9 and P/S ratio of 2.8. The dividend yield of Baxter International Inc. stocks is 1.8%. Baxter International Inc. had an annual average earning growth of 4.8% over the past 10 years. GuruFocus rated Baxter International Inc. the business predictability rank of 4-star.
Sold Out: Auxilium Pharmaceuticals Inc. (AUXL)
Bill Gates sold out his holdings in Auxilium Pharmaceuticals Inc.. His sale prices were between $22.07 and $30.34, with an estimated average price of $25.
Auxilium Pharmaceuticals Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1% a topical testosterone gel for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions as well as other products for urology and sexual health including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease. Auxilium Pharmaceuticals Inc. has a market cap of $1.21 billion; its shares were traded at around $28.28 with and P/S ratio of 9.6.
Sold Out: Allos Therapeutics Inc. (ALTH)
Bill Gates sold out his holdings in Allos Therapeutics Inc.. His sale prices were between $5.75 and $8.15, with an estimated average price of $6.8.
Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin the oxygen-carrying protein contained within red blood cells. Allos Therapeutics Inc. has a market cap of $694.3 million; its shares were traded at around $7.77 .
Sold Out: Vertex Pharmaceuticals Inc. (VRTX)
Bill Gates sold out his holdings in Vertex Pharmaceuticals Inc.. His sale prices were between $26.87 and $36.04, with an estimated average price of $30.1.
Vertex Pharmaceuticals Inc. discovers develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases inflammation cancer autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE) Vertex Pharmaceuticals Inc. has a market cap of $6.47 billion; its shares were traded at around $37.37 with and P/S ratio of 36.8. Vertex Pharmaceuticals Inc. had an annual average earning growth of 19.1% over the past 10 years.
Sold Out: Abbott Laboratories (ABT)
Bill Gates sold out his holdings in Abbott Laboratories. His sale prices were between $41.15 and $47.16, with an estimated average price of $44.2.
Abbott Laboratories is a global broad-based health care company devoted to discovering new medicines new technologies and new ways to manage health. Abbott products span the continuum of care from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Abbott comprehensive line of products encircles life itself addressing important health needs from infancy to the golden years. Abbott Laboratories has a market cap of $72.03 billion; its shares were traded at around $46.61 with a P/E ratio of 13.4 and P/S ratio of 2.4. The dividend yield of Abbott Laboratories stocks is 3.5%. Abbott Laboratories had an annual average earning growth of 4.4% over the past 10 years. GuruFocus rated Abbott Laboratories the business predictability rank of 5-star.
Also check out:
Bill & Melinda Gates Foundation buys CSX Corp., M&T Bank Corp., XTO Energy Inc., America Movil S.a.b. De C.v., Range Resources Corp., Cabot Oil & Gas Corp., Devon Energy Corp., sells Vertex Pharmaceuticals Inc., Aryx Therapeutics Inc., Regeneron Pharmaceuticals Inc., Ardea Biosciences, Inc., Pfizer Inc, Mylan Inc. Mandatory Convertible Preferr, Map Pharmaceuticals, Inc., Eli Lilly And Company, Johnson & Johnson, Intermune Inc., Biomarin Pharmaceutical Inc., Amag Pharmaceuticals Inc., Orexigen Therapeutics Inc., Allos Therapeutics Inc., Auxilium Pharmaceuticals Inc., Pharmasset Inc., Wyeth, Select Sector Spdrhealth Care, Xenoport Inc., Teva Pharmaceutical Industries Ltd., Scheringplough Corp., Merck & Co. Inc., Incyte Corp., Enteromedics Inc., China Medical Technologies Inc. Ads, Baxter International Inc., Abbott Laboratories during the 3-months ended 06/30/2009, according to the most recent filings of his investment company, Bill & Melinda Gates Foundation Trust. Bill Gates owns 38 stocks with a total value of $7.5 billion. These are the details of the buys and sells. New Purchases: AMX, COG, CSX, DVN, MTB, RRC, XTO,
Added Positions: MCD, TV,
Sold Out: ABT, ALTH, AMAG, ARYX, AUXL, BAX, BMRN, CMED, ETRM, INCY, ITMN, JNJ, LLY, MAPP, MRK, MYLNP, OREX, PFE, RDEA, REGN, SGP, TEVA, VRTX, VRUS, WYE, XLV, XNPT,
For the details of Bill Gates's stock buys and sells, go to the Link Here
This is the sector weightings of Bill Gates's portfolio:
| Technology |  1.8% |
|---|---|
| Financials | 49.5% |
| Telecommunications | 0.5% |
| Consumer Services | 20.8% |
| Health Care | 0.4% |
| Consumer Goods | 7.1% |
| Industrials | 11.2% |
| Basic Materials | 0.2% |
| Oil & Gas | 8.5% |
These are the top 5 holdings of Bill Gates
- Berkshire Hathaway Inc. (BRK-B) - 1,251,250 shares, 48.36% of the total portfolio
- McDonald's Corp. (MCD) - 6,867,500 shares, 5.27% of the total portfolio
- Canadian National Railway Company Fully (CNI) - 8,399,653 shares, 4.82% of the total portfolio
- Exxon Mobil Corp. (XOM) - 4,285,000 shares, 4% of the total portfolio
- Costco Wholesale Corp. (COST) - 6,128,000 shares, 3.74% of the total portfolio
Added: McDonald's Corp. (MCD, Financial)
Bill Gates added to his holdings in McDonald's Corp. by 7.85%. His purchase prices were between $51.97 and $59.87, with an estimated average price of $56.1. The impact to his portfolio due to this purchase was 0.38%. His holdings were 6,867,500 shares as of 06/30/2009.
McDonald's Corporation develops operates franchises and services a worldwide system of restaurants that prepare assemble package and sell a limited menu of value-priced foods. The company operates primarily in the quick-service hamburger restaurant business. All restaurants are operated by the company or under the terms of franchise arrangements by franchisees who are independent third parties or by affiliates operating under joint-venture agreements between the company and local business people. McDonald's Corp. has a market cap of $63.06 billion; its shares were traded at around $57.16 with a P/E ratio of 15.2 and P/S ratio of 2.6. The dividend yield of McDonald's Corp. stocks is 3.6%. McDonald's Corp. had an annual average earning growth of 7.2% over the past 10 years.
Added: Grupo Televisa S.a. Global Depositary (TV, Financial)
Bill Gates added to his holdings in Grupo Televisa S.a. Global Depositary by 20.86%. His purchase prices were between $15.19 and $17.78, with an estimated average price of $16.6. The impact to his portfolio due to this purchase was 0.34%. His holdings were 8,690,800 shares as of 06/30/2009.
Grupo Televisa S.A is the largest media company in the Spanish-speaking world and a major player in the international entertainment business. They have interests in Television production broadcasting international distribution of television programming direct-to-home satellite services publishing music recording radio production and broadcasting cable television professional sports and show business promotions paging services feature film production and distribution and dubbing. with a P/E ratio of 447.6. The dividend yield of Grupo Televisa S.a. Global Depositary stocks is 3.7%. Grupo Televisa S.a. Global Depositary had an annual average earning growth of 12.3% over the past 10 years. GuruFocus rated Grupo Televisa S.a. Global Depositary the business predictability rank of 3-star.
New Purchase: CSX Corp. (CSX, Financial)
Bill Gates initiated holdings in CSX Corp.. His purchase prices were between $27.47 and $36.52, with an estimated average price of $31.7. The impact to his portfolio due to this purchase was 0.69%. His holdings were 1,500,000 shares as of 06/30/2009.
CSX Corporation's unique combination of rail container-shipping intermodal and logistics services provides global reach that's second to none. The company's goal advanced at each of its business units is to provide efficient competitive transportation and related services for customers. CSX Corp. has a market cap of $17.01 billion; its shares were traded at around $43.46 with a P/E ratio of 13.7 and P/S ratio of 1.5. The dividend yield of CSX Corp. stocks is 2.1%. CSX Corp. had an annual average earning growth of 12.8% over the past 10 years.
New Purchase: M&T Bank Corp. (MTB, Financial)
Bill Gates initiated holdings in M&T Bank Corp.. His purchase prices were between $45.5 and $59.11, with an estimated average price of $50.3. The impact to his portfolio due to this purchase was 0.68%. His holdings were 999,998 shares as of 06/30/2009.
M&T Bank Corp is a bank holding company. They have two primary bank subsidiaries: Manufacturers and Traders Trust Company and M&T Bank National Association. The banks collectively offer a wide range ofcommercial banking trust and investment services to their customers. From time to time M&T Bank considers acquiring banks thrift institutionsbranch offices or other businesses within markets currently served or in other nearby markets. M&T Bank Corp. has a market cap of $6.8 billion; its shares were traded at around $61.24 with a P/E ratio of 21.5 and P/S ratio of 1.6. The dividend yield of M&T Bank Corp. stocks is 4.6%. M&T Bank Corp. had an annual average earning growth of 10.2% over the past 10 years. GuruFocus rated M&T Bank Corp. the business predictability rank of 4-star.
New Purchase: XTO Energy Inc. (XTO, Financial)
Bill Gates initiated holdings in XTO Energy Inc.. His purchase prices were between $33.1 and $44.13, with an estimated average price of $38.8. The impact to his portfolio due to this purchase was 0.62%. His holdings were 1,210,000 shares as of 06/30/2009.
XTO Energy Inc. is engaged in the acquisition development exploitation and exploration of producing oil and gas properties and in the production processing marketing and transportation of oil and natural gas. The company has grown primarily through acquisitions of proved oil and gas reserves followed by development and exploitation activities and strategic acquisitions of additional interests in or near such acquired properties. XTO Energy Inc. has a market cap of $22.63 billion; its shares were traded at around $39.04 with a P/E ratio of 11.3 and P/S ratio of 3. The dividend yield of XTO Energy Inc. stocks is 1.2%. XTO Energy Inc. had an annual average earning growth of 36.6% over the past 10 years. GuruFocus rated XTO Energy Inc. the business predictability rank of 5-star.
New Purchase: America Movil S.a.b. De C.v. (AMX, Financial)
Bill Gates initiated holdings in America Movil S.a.b. De C.v.. His purchase prices were between $30.98 and $38.32, with an estimated average price of $35.5. The impact to his portfolio due to this purchase was 0.52%. His holdings were 999,984 shares as of 06/30/2009.
American Movil is the leading provider of wireless communications services in Mexico. Through their subsidiary Radiom?vil Dipsa which operates under the trademark Telcel they provide cellular telecommunications service in all nine regions in Mexico with a network covering approximately 31.4% of the geographical area of Mexico including all major cities and approximately 89.6% of Mexico 's population. America Movil S.a.b. De C.v. has a market cap of $84.17 billion; its shares were traded at around $46.76 with a P/E ratio of 14.7 and P/S ratio of 3.3. The dividend yield of America Movil S.a.b. De C.v. stocks is 1%. America Movil S.a.b. De C.v. had an annual average earning growth of 45.5% over the past 5 years.
New Purchase: Cabot Oil & Gas Corp. (COG, Financial)
Bill Gates initiated holdings in Cabot Oil & Gas Corp.. His purchase prices were between $28.34 and $35.56, with an estimated average price of $31.8. The impact to his portfolio due to this purchase was 0.32%. His holdings were 775,550 shares as of 06/30/2009.
Cabot Oil & Gas Corp. is an independent oil and gas company engaged in the exploration development acquisition and exploitation of oil and gas properties located in four areas of the United States: the onshore Texas and Louisiana Gulf Coast; the Rocky Mountains; Appalachia; and the Mid-Continent or Anadarko Basin. Cabot Oil & Gas Corp. has a market cap of $3.77 billion; its shares were traded at around $36.4 with a P/E ratio of 21.1 and P/S ratio of 4. The dividend yield of Cabot Oil & Gas Corp. stocks is 0.3%. Cabot Oil & Gas Corp. had an annual average earning growth of 16.2% over the past 10 years. GuruFocus rated Cabot Oil & Gas Corp. the business predictability rank of 4-star.
New Purchase: Range Resources Corp. (RRC, Financial)
Bill Gates initiated holdings in Range Resources Corp.. His purchase prices were between $39.89 and $46.81, with an estimated average price of $43.4. The impact to his portfolio due to this purchase was 0.32%. His holdings were 575,000 shares as of 06/30/2009.
Range Resources Corp. acquires develops and finances oil and gas properties in the U.S. They seek to build value primarily through lower-risk development drilling and acquisitions while to a lesser degree pursuing higher risk exploitation and exploration projects on their extensive inventory of undeveloped acreage. Through its wholly owned subsidiary Independent Producer Finance the company also provides financing to small oil and gas producers by purchasing term overriding royalty interests in their properties. Range Resources Corp. has a market cap of $7.8 billion; its shares were traded at around $49.83 with a P/E ratio of 44.9 and P/S ratio of 6. The dividend yield of Range Resources Corp. stocks is 0.3%. Range Resources Corp. had an annual average earning growth of 4.1% over the past 10 years.
New Purchase: Devon Energy Corp. (DVN, Financial)
Bill Gates initiated holdings in Devon Energy Corp.. His purchase prices were between $48.79 and $65.53, with an estimated average price of $58.1. The impact to his portfolio due to this purchase was 0.3%. His holdings were 407,500 shares as of 06/30/2009.
Devon Energy Corporation is an independent energy company engaged primarily in oil and gas exploration development and production and in the acquisition of producing properties. Devon currently owns oil and gas properties concentrated in four operating divisions: the Northern Division; the Southern Division; Canada; and the International Division. Devon Energy Corp. has a market cap of $27.58 billion; its shares were traded at around $62.13 with a P/E ratio of 12.2 and P/S ratio of 1.9. The dividend yield of Devon Energy Corp. stocks is 1%. Devon Energy Corp. had an annual average earning growth of 18.1% over the past 10 years. GuruFocus rated Devon Energy Corp. the business predictability rank of 4.5-star.
Sold Out: Johnson & Johnson (JNJ, Financial)
Bill Gates sold out his holdings in Johnson & Johnson. His sale prices were between $50.07 and $56.14, with an estimated average price of $53.7.
Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. The company's worldwide business is divided into three segments: Consumer; Pharmaceutical; and Professional. Johnson & Johnson has a market cap of $166.68 billion; its shares were traded at around $60.49 with a P/E ratio of 13.5 and P/S ratio of 2.7. The dividend yield of Johnson & Johnson stocks is 3.2%. Johnson & Johnson had an annual average earning growth of 12.5% over the past 10 years. GuruFocus rated Johnson & Johnson the business predictability rank of 4.5-star.
Sold Out: Aryx Therapeutics Inc. (ARYX, Financial)
Bill Gates sold out his holdings in Aryx Therapeutics Inc.. His sale prices were between $3.47 and $5.98, with an estimated average price of $4.4.
ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has three products in Phase 2 clinical trials: ATI-7505 for the treatment of various gastrointestinal disorders ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots and ATI-2042 for the treatment of atrial fibrillation. Aryx Therapeutics Inc. has a market cap of $97.7 million; its shares were traded at around $3.57 with and P/S ratio of 5.
Sold Out: Regeneron Pharmaceuticals Inc. (REGN, Financial)
Bill Gates sold out his holdings in Regeneron Pharmaceuticals Inc.. His sale prices were between $12.94 and $18.21, with an estimated average price of $15.2.
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers develops and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM FunctionomicsTM and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity rheumatoid arthritis cancer allergies asthma amyotrophic lateral sclerosis constipating conditions ischemia and other diseases and disorders. (PRESS RELEASE) Regeneron Pharmaceuticals Inc. has a market cap of $1.82 billion; its shares were traded at around $22.77 with and P/S ratio of 7.6.
Sold Out: Ardea Biosciences, Inc. (RDEA)
Bill Gates sold out his holdings in Ardea Biosciences, Inc.. His sale prices were between $9.33 and $15.73, with an estimated average price of $13.6.
IntraBiotics Pharmaceuticals Inc. develops and intends to commercialize new antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. The company obtained statistically significant data from human clinical trials that test for preliminary safety and efficacy that indicate each of the products are well tolerated and support further efficacy trials. The new antibiotics may solve medical problems for patients who have few or no satisfactory alternatives. Ardea Biosciences, Inc. has a market cap of $331.4 million; its shares were traded at around $18.56 with and P/S ratio of 1090.1.
Sold Out: Pfizer Inc (PFE)
Bill Gates sold out his holdings in Pfizer Inc. His sale prices were between $12.89 and $15.04, with an estimated average price of $14.3.
Pfizer Inc is a research-based global pharmaceutical company that discovers and develops innovative value-added products that improve the quality of life of people around the world and help them enjoy longer healthier and more productive lives. Pfizer has three business segments: health care animal health and consumer health care. Its products are available in numerous countries. (Company Press Release) Pfizer Inc has a market cap of $113.77 billion; its shares were traded at around $16.86 with a P/E ratio of 7.3 and P/S ratio of 2.3. The dividend yield of Pfizer Inc stocks is 3.8%. Pfizer Inc had an annual average earning growth of 11% over the past 10 years. GuruFocus rated Pfizer Inc the business predictability rank of 2.5-star.
Sold Out: Intermune Inc. (ITMN)
Bill Gates sold out his holdings in Intermune Inc.. His sale prices were between $11.32 and $15.18, with an estimated average price of $13.
InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas several of which are in mid-or advanced-stage human testing known as clinical trials. Intermune Inc. has a market cap of $718.7 million; its shares were traded at around $15.6 with and P/S ratio of 14.9.
Sold Out: Map Pharmaceuticals, Inc. (MAPP)
Bill Gates sold out his holdings in Map Pharmaceuticals, Inc.. His sale prices were between $2.65 and $12.09, with an estimated average price of $6.4.
Located in Mountain View California MAP Pharmaceuticals Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Map Pharmaceuticals, Inc. has a market cap of $192.2 million; its shares were traded at around $9.33 .
Sold Out: Eli Lilly And Company (LLY)
Bill Gates sold out his holdings in Eli Lilly And Company. His sale prices were between $31.73 and $34.94, with an estimated average price of $33.5.
Eli Lilly and Company discovers develops manufactures and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Eli Lilly And Company has a market cap of $39.19 billion; its shares were traded at around $34.11 with a P/E ratio of 7.7 and P/S ratio of 1.9. The dividend yield of Eli Lilly And Company stocks is 5.7%. Eli Lilly And Company had an annual average earning growth of 4.4% over the past 10 years. GuruFocus rated Eli Lilly And Company the business predictability rank of 4.5-star.
Sold Out: Biomarin Pharmaceutical Inc. (BMRN)
Bill Gates sold out his holdings in Biomarin Pharmaceutical Inc.. His sale prices were between $12.42 and $15.94, with an estimated average price of $14.
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating life-threatening chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product BM101 for the treatment of mucopolysaccharidosis-I or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans. Biomarin Pharmaceutical Inc. has a market cap of $1.61 billion; its shares were traded at around $16.07 with a P/E ratio of 133.8 and P/S ratio of 5.5.
Sold Out: Amag Pharmaceuticals Inc. (AMAG)
Bill Gates sold out his holdings in Amag Pharmaceuticals Inc.. His sale prices were between $40.32 and $54.64, with an estimated average price of $50.2.
AMAG Pharmaceuticals Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol the company's key product candidate is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex? the company's other product under development is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005 the company received an approvable letter from the FDA with respect to Combidex subject to certain conditions. Amag Pharmaceuticals Inc. has a market cap of $709.4 million; its shares were traded at around $41.67 with and P/S ratio of 366.
Sold Out: Orexigen Therapeutics Inc. (OREX)
Bill Gates sold out his holdings in Orexigen Therapeutics Inc.. His sale prices were between $2.06 and $5.21, with an estimated average price of $3.4.
OREXIGEN THERAPEUTICS INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders including obesity. The Company's lead combination product candidates targeted for obesity are Contrave which is in Phase III clinical trials and Empatic which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Orexigen Therapeutics Inc. has a market cap of $283.5 million; its shares were traded at around $8.17 with and P/S ratio of 3221.6.
Sold Out: Pharmasset Inc. (VRUS)
Bill Gates sold out his holdings in Pharmasset Inc.. His sale prices were between $8.55 and $11.46, with an estimated average price of $10.
PHARMASSET INC is a clinical-stage pharmaceutical company committed to discovering developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus hepatitis C virusand human immunodeficiency virus. Pharmasset Inc. has a market cap of $507.4 million; its shares were traded at around $18.05 with and P/S ratio of 273.3.
Sold Out: Wyeth (WYE)
Bill Gates sold out his holdings in Wyeth. His sale prices were between $41.55 and $44.74, with an estimated average price of $43.5.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery development manufacturing and marketing of pharmaceuticals vaccines biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals Wyeth Consumer Healthcare and Fort Dodge Animal Health. Wyeth has a market cap of $64.17 billion; its shares were traded at around $48.11 with a P/E ratio of 13.6 and P/S ratio of 2.8. The dividend yield of Wyeth stocks is 2.5%. Wyeth had an annual average earning growth of 5.8% over the past 10 years.
Sold Out: Xenoport Inc. (XNPT)
Bill Gates sold out his holdings in Xenoport Inc.. His sale prices were between $14.27 and $21.41, with an estimated average price of $18.5.
XenoPort Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs. Xenoport Inc. has a market cap of $492.4 million; its shares were traded at around $18.03 with and P/S ratio of 11.7.
Sold Out: Teva Pharmaceutical Industries Ltd. (TEVA)
Bill Gates sold out his holdings in Teva Pharmaceutical Industries Ltd.. His sale prices were between $43.89 and $48.6, with an estimated average price of $45.9.
TEVA Pharmaceuticals USA the business is to develop manufacture and market generic pharmaceuticals. Teva USA sells its products to chains wholesalers distributors hospitals managed care entities and government agencies. The company markets a variety of dosage forms including both extended and immediate release tablets and capsules creams ointments solutions and suspensions. Key therapeutic areas are the analgesic anti-infective cardiovascular CNS dermatological and anti-inflammatory categories. Teva Pharmaceutical Industries Ltd. has a market cap of $44.91 billion; its shares were traded at around $51.38 with a P/E ratio of 17 and P/S ratio of 4. The dividend yield of Teva Pharmaceutical Industries Ltd. stocks is 0.9%. Teva Pharmaceutical Industries Ltd. had an annual average earning growth of 42.6% over the past 10 years. GuruFocus rated Teva Pharmaceutical Industries Ltd. the business predictability rank of 2.5-star.
Sold Out: Scheringplough Corp. (SGP)
Bill Gates sold out his holdings in Scheringplough Corp.. His sale prices were between $22.05 and $24.5, with an estimated average price of $23.4.
Schering-Plough Corporation and its subsidiaries are engaged in the discovery development manufacturing and marketing of pharmaceutical products worldwide. The company operates primarily in the prescription pharmaceutical marketplace. However where appropriate the company has sought regulatory approval to switch prescription products to over-the-counter status as a means of extending a product's life cycle. Scheringplough Corp. has a market cap of $46.28 billion; its shares were traded at around $28.33 with a P/E ratio of 15.7 and P/S ratio of 2.5. The dividend yield of Scheringplough Corp. stocks is 0.9%.
Sold Out: Merck & Co. Inc. (MRK)
Bill Gates sold out his holdings in Merck & Co. Inc.. His sale prices were between $23.13 and $27.2, with an estimated average price of $25.5.
Merck & Co. Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891 Merck discovers develops manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Merck & Co. Inc. has a market cap of $69.32 billion; its shares were traded at around $32.87 with a P/E ratio of 10.1 and P/S ratio of 2.9. The dividend yield of Merck & Co. Inc. stocks is 4.6%.
Sold Out: Incyte Corp. (INCY)
Bill Gates sold out his holdings in Incyte Corp.. His sale prices were between $2.17 and $3.84, with an estimated average price of $2.9.
Incyte Corp is a drug discovery company that is using its expertise in genomics medicinal chemistry and molecular cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer. Incyte Corp. has a market cap of $624.9 million; its shares were traded at around $6.42 with and P/S ratio of 159.4. Incyte Corp. had an annual average earning growth of 6.9% over the past 5 years.
Sold Out: Enteromedics Inc. (ETRM)
Bill Gates sold out his holdings in Enteromedics Inc.. His sale prices were between $1.28 and $3.9, with an estimated average price of $2.5.
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity and following an in-depth analysis of how the vagus nerve affects food intake and processing EnteroMedics has selected obesity management as its primary focus. Enteromedics Inc. has a market cap of $98.5 million; its shares were traded at around $3.28 .
Sold Out: China Medical Technologies Inc. Ads (CMED)
Bill Gates sold out his holdings in China Medical Technologies Inc. Ads. His sale prices were between $18.11 and $24.93, with an estimated average price of $21.3.
China Medical Technologies Inc. is a China-based medical device company that develops manufactures and markets products using HIFU for the treatment of solid cancers and benign tumors in China. They design and development HIFU tumor therapy devices in China. Their HIFU therapy system is SFDA-approved and has been used to treat over 20000 patient cases. In addition they offer an integrated luminescence immunoassay IVD system using ECLIA technology to detect and monitor various diseases and disorders through laboratory evaluation and analysis of blood or urine. China Medical Technologies Inc. Ads has a market cap of $429.2 million; its shares were traded at around $15.69 with a P/E ratio of 6.7 and P/S ratio of 3.5.
Sold Out: Baxter International Inc. (BAX)
Bill Gates sold out his holdings in Baxter International Inc.. His sale prices were between $47.3 and $52.25, with an estimated average price of $49.8.
Baxter engages in the worldwide development manufacture and distribution of a diversified line of products systems and services used primarily in the health-care field. The company's products are used by hospitals clinical and medical research laboratories blood and dialysis centers rehabilitation centers nursing homes doctors' offices and by patients at home under physician supervision. Baxter International Inc. has a market cap of $34.38 billion; its shares were traded at around $56.82 with a P/E ratio of 15.9 and P/S ratio of 2.8. The dividend yield of Baxter International Inc. stocks is 1.8%. Baxter International Inc. had an annual average earning growth of 4.8% over the past 10 years. GuruFocus rated Baxter International Inc. the business predictability rank of 4-star.
Sold Out: Auxilium Pharmaceuticals Inc. (AUXL)
Bill Gates sold out his holdings in Auxilium Pharmaceuticals Inc.. His sale prices were between $22.07 and $30.34, with an estimated average price of $25.
Auxilium Pharmaceuticals Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1% a topical testosterone gel for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions as well as other products for urology and sexual health including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease. Auxilium Pharmaceuticals Inc. has a market cap of $1.21 billion; its shares were traded at around $28.28 with and P/S ratio of 9.6.
Sold Out: Allos Therapeutics Inc. (ALTH)
Bill Gates sold out his holdings in Allos Therapeutics Inc.. His sale prices were between $5.75 and $8.15, with an estimated average price of $6.8.
Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin the oxygen-carrying protein contained within red blood cells. Allos Therapeutics Inc. has a market cap of $694.3 million; its shares were traded at around $7.77 .
Sold Out: Vertex Pharmaceuticals Inc. (VRTX)
Bill Gates sold out his holdings in Vertex Pharmaceuticals Inc.. His sale prices were between $26.87 and $36.04, with an estimated average price of $30.1.
Vertex Pharmaceuticals Inc. discovers develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases inflammation cancer autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE) Vertex Pharmaceuticals Inc. has a market cap of $6.47 billion; its shares were traded at around $37.37 with and P/S ratio of 36.8. Vertex Pharmaceuticals Inc. had an annual average earning growth of 19.1% over the past 10 years.
Sold Out: Abbott Laboratories (ABT)
Bill Gates sold out his holdings in Abbott Laboratories. His sale prices were between $41.15 and $47.16, with an estimated average price of $44.2.
Abbott Laboratories is a global broad-based health care company devoted to discovering new medicines new technologies and new ways to manage health. Abbott products span the continuum of care from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Abbott comprehensive line of products encircles life itself addressing important health needs from infancy to the golden years. Abbott Laboratories has a market cap of $72.03 billion; its shares were traded at around $46.61 with a P/E ratio of 13.4 and P/S ratio of 2.4. The dividend yield of Abbott Laboratories stocks is 3.5%. Abbott Laboratories had an annual average earning growth of 4.4% over the past 10 years. GuruFocus rated Abbott Laboratories the business predictability rank of 5-star.
Also check out:
